Table 2.
Effects of CYP2D6 genotype and age on concentration-to-dose ratio and metabolic ratio of flecainide
| Sex (M/F) | Concentration-to-dose ratio | Metabolic ratio | ||||
|---|---|---|---|---|---|---|
| CYP2D6 genotype groups | Middle aged | Elderly | Middle aged | Elderly | Middle aged | Elderly |
| Hom-EMs | 17/7 | 6/4 | 92 ± 35 | 115 ± 48 | 2.4 ± 0.9 | 2.5 ± 1.4 |
| (78, 106) | (85, 144) | (2.0, 2.7) | (1.7, 3.4) | |||
| Het-EMs | 36/7 | 10/3 | 104 ± 34 | 144 ± 45* | 2.7 ± 1.4 | 4.3 ± 2.7* |
| (94, 114) | (120, 169) | (2.3, 3.1) | (2.8, 5.7) | |||
| IMs/PMs | 12/1 | 5/3 | 133 ± 48† | 171 ± 48† | 4.1 ± 2.3† | 6.0 ± 2.2*† |
| (108, 159) | (138, 204) | (2.9, 5.4) | (4.5, 7.6) | |||
*
Significant difference between middle aged and elderly was observed at P < 0.05.
†
Significant difference between hom-EMs and IMs/PMs was observed at P < 0.05. Results are presented as number or mean ± standard deviation (95% CI). Hom-EMs, homozygous extensive metabolizers; Het-EMs, heterozygous extensive metabolizers; IMs/PMs, intermediate and poor metabolizers; M/F, male/female.